EP0406734A2

2-(Aminoaryl)indoles and indolines, a process for their preparation and their use as medicaments.

Abstract

There are described compounds of the formula where A is CH or N;X is hydrogen, loweralkyl, halogen, trifluromethyl, loweralkoxy, arylloweralkoxy, hydroxy or phenylamino;Y is hydrogen, loweralkyl, halogen, loweralkoxy, arylloweralkoxy or hydroxy;R1 is hydrogen or loweralkyl;R2 is hydrogen, loweralkyl, formyl, alkylcarbonyl, arylloweralkylcarbonyl, arylcarbonyl, alkoxycarbonyl, arylloweralkoxycarbonyl or aryloxycarbonyl;R3 is hydrogen, alkyl, alkylcarbonyl, arylloweralkylcarbonyl, arylcarbonyl, alkoxycarbonyl, arylloweralkoxycarbonyl, aryloxycarbonyl or -CH2CO2C2H5;which compounds are useful as topical antiinflammatory agents for the treatment of skin disorders, and a process for their preparation.

EP0406734A2, drawing sheet 1
Sheet 1 of 96

Term

Term ended

Projected expiry passed 30 June 2010, 16.2 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

12 claims: 12 independent, 0 dependent

  1. 1
    A compound of the formula I where A is CH or N;X is hydrogen, loweralkyl, halogen, trifluromethyl, loweralkoxy, arylloweralkoxy, hydroxy or phenylamino;Y is hydrogen, loweralkyl, halogen, loweralkoxy, arylloweralkoxy or hydroxy;R 1 is hydrogen or loweralkyl;R 2 is hydrogen, loweralkyl, formyl, alkylcarbonyl, arylloweralkylcarbonyl, arylcarbonyl, alkoxycarbonyl, arylloweralkoxycarbonyl or aryloxycarbonyl;R 3 is hydrogen, alkyl, alkylcarbonyl, arylloweralkylcarbonyl, arylcarbonyl, alkoxycarbonyl, arylloweralkoxycarbonyl, aryloxycarbonyl or -CH 2 C0 2 C 2 Hs;with the proviso that when A is CH, Y is hydrogen, R 3 is hydrogen and -NR, R 2 is 2-amino, the group X is not hydrogen, 5-chloro or 5-bromo, or a pharmaceutically acceptable acid addition salt thereof .
  2. 2
    A compound as defined in claim 1 wherein R 1 is hydrogen and R 2 is hydrogen, loweralkyl, formyl, alkylcarbonyl or alkoxycarbonyl.
  3. 3
    A compound as defined in claim 2 wherein A is CH.
  4. 4
    The compound as defined in claim 1 which is 2-(2-amino-5-chlorophenyl)-2,3-dihydro-1 H-indole or a pharmaceutically acceptable acid addition salt thereof.
  5. 5
    The compound as defined in claim 1 which is 2-(2-amino-5-methoxyphenyl)-1 H-indole or a pharmaceutically acceptable acid addition salt thereof.
  6. 6
    The compound as defined in claim 1, which is 2,2-dimethyl-N-[2-(2,3-dihydro-1 H-indol-2-yl)phenyl]-propanamide or a pharmaceutically acceptable acid addition salt thereof.
  7. 7
    The compound as defined in claim 1, which is 2-(2-aminophenyl)-5-methoxy-2,3-dihydro-1H-indole or a pharmaceutically acceptable acid addition salt thereof.
  8. 8
    The compound as defined in claim 1, which is 1-(1,1-dimethylethoxycarbonyl)-2-(2-aminophenyl)-2,3-dihydro-1 H-indole or a pharmaceutically acceptable acid addition salt thereof.
  9. 9
    The compound as defined in claim 1, which is 2-[2-(octyloxycarbonylamino)-phenyl]-2,3-dihydro-1 H-indole or a pharmaceutically acceptable acid addition salt thereof.
  10. 10
    A pharmaceutical composition which comprises a compound as defined in claim 1 as the active ingredient and a suitable carrier therefor.
  11. 11
    Use of a compound as defined in claim 1 for the preparation of a topical agent which is effective for treating an inflammatory skin disorder.
  12. 12
    A process for the preparation of a compound as defined in claim 1, which comprises a) allowing a compound of the formula V where A, X and Y are as defined, to undergo Fischer indole synthesis to afford a compound of the formula la, where A, X and Y are as defined,R 1 is hydrogen or loweralkyl, R 3 is hydrogen, and there is a double bond in 2,3-position of the indole moiety, b) optionally reacting a compound of the formula la, as obtained in step a), with formic acid and 1,3-dicyclohexylcarbodiimide, to afford a compound of the formula I,, where A, X and Y are as defined, R 1 is hydrogen or loweralkyl, Ra is hydrogen and R 2 is form yl, c) optionally reducing a compound of the formula la as obtained in step b) with LiAIH 4 to afford a compound of the formula I, where A, X and Y are as defined, R 1 is hydrogen or loweralkyl, R 3 is hydrogen and R 2 is methyl, d) optionally treating a compound of the formula la where A, Ri, R 2 and X are as defined and Y is methoxy, with BBr 3 to afford a compound of the formula I, where Y is hydroxy, e) optionally reducing a compound of the formula la where A, X and Y are as defined, R 1 is hydrogen or loweralkyl, R 2 is hydrogen or methyl and R 3 is hydrogen, with a complex borohydride to afford a compound of the formula Ib, where there is no double bond in 2,3-position of the indole moiety, f) optionally alkylating a compound of the formula I, where A, X and Y are as defined, R 1 is hydrogen or loweralkyl, R 2 is hydrogen and R 3 is hydrogen, to afford a compound of the formula I, where R 1 and R 2 are independently loweralkyl, A, X and Y are as defined and R 3 is hydrogen, g) optionally reacting a compound of the formula I where A, X and Y are as defined, R 1 is as defined, R 2 is hydrogen, loweralkyl or formyl and R 3 is hydrogen, with (CH 3 ) 3 COC(O)OC(CH 3 ) 3 to afford a compound of the formula I, where R 3 is h) optionally reacting a compound of the formula I, where A, X and Y are as defined, R, is loweralkyl, R 2 is as defined but is not hydrogen, R 3 is hydrogen, with a compound of the formula RsCOCI or the corresponding acid anhydride, where Rs is alkyl, arylloweralkyl, aryl, alkoxy, arylloweralkoxy or aryloxy to afford a compound of the formula I, where R 3 is RsCO-, where Rs has the above meaning, i) optionally reacting a compound of the formula 1, where R 3 is hydrogen, at least one of the substituents R, and R 2 is hydrogen and R 2 is not formyl, with benzyloxycarbonyl chloride or N-(benzyloxycarbonyl)-succinimide to afford a compound of the formula I, where R, is as defined and R 2 is the group then reacting the compound obtained with a compound of the formula R 5 COCl or the corresponding acid anhydride to afford a compound of the formula I, where R, is hydrogen, R 2 is the group and R 3 is RsCO- where R 5 is as defined in step h) above, and optionally subjecting the compound obtained to a hydrogenolysis to afford a compound of the formula I, where R 1 and R 2 are both hydrogen, and R 3 is RsCO-, j) optionally reacting a compound of the formula I where A, X and Y are as defined, R, is hydrogen or loweralkyl, R 2 is hydrogen, loweralkyl or formyl and R 3 is hydrogen, with ethylbromoacetate to afford a compound of the formula I where R 3 is k) optionally reacting a compound of the formula I, where A, X and Y are as defined, Ri, R 2 and R 3 are hydrogen, with at least 2 equivalents of a compound of the formula -Hal, where Hal is CI or Br and R s is as defined in step h) above, to afford a compound of the formula I, where R 1 is hydrogen and R 2 and R 3 are both I) optionally reacting a compound of the formula 1, where A, X and Y are as defined and R 1 , R 2 and R 3 are hydrogen, with one equivalent or less of a compound of the formula -Hal, where Hal is CI or Br and R s is as defined in step h) above, to afford a compound of the formula I, where R 1 and R 3 are hydrogen and R 2 is and m) optionally introducing into a compound of the formula I, where A, X and Y are as defined, R 1 is hydrogen, R 2 is - and R 3 is hydrogen, the groups or as described in steps g), h) and j) above.